sitagliptin apc instytut 25 mg film - coated tablets
25 mg film - coated tablets
sitagliptin apc instytut 50 mg film - coated tablets
50 mg film - coated tablets
sitagliptin apc instytut 100 mg film - coated tablets
100 mg film - coated tablets
rivaroxaban apc 20 mg film - coated tablets
20 mg film - coated tablets
rivaroxaban apc 15 mg film - coated tablets
15 mg film - coated tablets
rivaroxaban apc 10 mg film - coated tablets
10 mg film - coated tablets
rivaroxaban apc 2,5 mg film - coated tablets
2,5 mg film - coated tablets
cevenfacta
laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - Антихеморагични - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.
ceprotin
takeda manufacturing austria ag - човешки протеин С - purpura fulminans; protein c deficiency - Антитромботични агенти - ceprotin is indicated for prophylaxis and treatment of purpura fulminans coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein c deficiency.
unituxin
united therapeutics europe ltd - dinutuximab - невробластом - Антинеопластични средства - unituxin е показан за лечение на високо рискови невробластом при пациенти на възраст 12 месеца, за да 17years, които преди това са получили индукционна химиотерапия и постигне поне частичен отговор, последван от myeloablative терапия и автоложна трансплантация (asct). Той се прилага в комбинация с гранулоцит-макрофаг колония-стимулиращ фактор (gm-csf), интерлевкин-2 (il-2) и изотретиноин.